Member Info for Saintsmith

Thank you very much doc and wigster .
As a relatively new investor I find your review extremely helpful.

Looking forward to updates from the AGM .
TIA to all who are attending .

Nearly 300. 000 covid cases a day and this is without mass , free testing . I imagine this number is vastly underestimated with all the cases not accounted for .

And it is still summer .

https://apple.news/AqKHXDu90RsS4fc9VgAv6jw

Have you ever thought more people read this board than post on it baby ?

@karean , your post has been ticked 15 times .

As we have seen today with abingdons share price going up around 40% with a DHSC settlement of only £6.3 million .
You can bet your bottom dollar that once our dispute for over 10 x that amount is settled our share price will rise multiples of that !!

Talk
Agent Selection and Master Protocols for Evaluation of Candidate COVID-19 Therapeutics and Lessons Learned for Future Pandemics
Working in an unprecedented timeframe, the Accelerating COVID-19 Therapeutic Interventions and Vaccines (ACTIV) public-private partnership rapidly designed a unique therapeutic agent intake and assessment process for multiple types of candidate treatments (preclinical and clinical antivirals, immune modulators, SARS-CoV-2 neutralizing antibodies, and organ supportive) for COVID-19, reviewing over 800 and advancing over 30 agents to trials for testing. ACTIV also developed and launched ten master protocols between April 2020 and August 2021 to allow for the coordinated and efficient evaluation of these over 30 investigational therapeutic agents. The ACTIV master protocols were designed with a portfolio approach to serve multiple patient populations with COVID-19: outpatient mild to moderately ill, inpatient moderately ill, and inpatient critically ill and designed to test the spectrum of the disease pathophysiology. Each protocol, either adaptive or pragmatic, was designed to efficiently select those treatments that provide benefit to patients while rapidly eliminating those that were either not effective or safe. For both the agent prioritization and master protocol development ACTIV has captured lessons learned that may be useful in meeting the challenges of a future pandemic.

Stacey Adam
Biography
Stacey plays a leadership role at the FNIH, helping to lead many public-private partnerships, such as Accelerating COVID-19 Therapeutic Interventions and Vaccines (ACTIV) the PPP that evaluated hundreds of available therapeutic agents with potential application for COVID-19, prioritized them, and designed and launched multiple master protocols to test them. Stacey oversees the Cancer, Metabolic Diseases and Clinical COVID Research portfolios at the Foundation for the National Institute of Health (FNIH). Beyond ACTIV other major partnerships under her guidance include the two steering committees of the Biomarkers Consortium and their projects, Partnership for Accelerating Cancer Therapies (PACT), and the Lung Master protocol (Lung-MAP) clinical trial. Prior to FNIH, she was a Manager at Deloitte Consulting within the Federal Life Sciences and Healthcare Strategy. She received her PhD at Duke and postdoctoral training at Stanford.

Interesting story today about DAM health .

https://apple.news/AZGk-1QucSmSvNF2ykDExYQ

It’s better with a second viewing to be fair .

U.K. approval can’t come soon enough with cases rising rapidly.

https://apple.news/ADRJGA_jjSXC6K7ZeHnWFFw

Who edited that video ?
Someone’s 10 year old child .
The words and descriptions on that advert are dreadful .

Like the wise man Wilson I have also blocked BYP.
He is a self confessed trader who ramps when he is long and is totally negative when he is short ..

We all have bad days but he has patterns in his positivity/ negativity , they usually coincide with his trades .
Not an honest individual .

Pi100, if you are not invested here and hate the share so much why do you spend so much time on this board constantly moaning ?
Try sharing a bit of positive research like my griproom article ;)
Or honour the bet you made with harchris and clear off . Your credibility is shot to pieces old boy .
What , what .

I think this article is more appropriate than ever , especially with our links to TATA and radio silence from the board .

https://www.griproom.com/fun/10-signs-your-company-is-about-to-be-acquired

Everybody voting In jerseys local elections are been asked to take LFT before voting .
I’m not sure how or if this will be monitored .

@pi100 .
Didn’t you lose a bet and promise not to post on here again .
Man of your word ??

As always patience is required ATS.

However there are factors that could easily arise and change this SP drastically for the better .
Things can change quickly and with only 72 million shares available this can fly given the right circumstances .

As winter approaches and we are already seeing a surge in covid cases in the U.K. and the world a large order may drop in our favour at any time.

This rise is also based on many millions LESS tests than this time last year so many cases go undetected .

Tata md express PCR could become a very popular diagnostics tool in India and we may see many multiple units deployed and sold in India .

Our monkey pox tests may well be being prepared for sale for the WHO and unicef . ( we were first responders with our covid tests ) it could happen again .

A DHSC resolution or compromise to inject many more millions into our bank balance .

The list goes on .

You could be waiting until you retire or any of the above could happen by Christmas .

You and only you have the choice of when to press that button ..

It is all about timing in this game .

WHO is supplying WHO ?

https://www.reuters.com/business/healthcare-pharmaceuticals/who-getting-monkeypox-tests-africa-urges-vaccine-readiness-2022-06-16/

Well done with your counter claim speculation Kaeren .
You called it well !

It was overdue and shows some grit and confidence from the company .

I don’t see it going to court and I imagine with the rising covid case rates in the U.K. and India that an agreement may be made between NCYT and the DHSC before the winter .

Hmmmm .

“For LFT requirements UKHSA does not seek to procure kits which are exclusively nasopharyngeal, oropharyngeal or exclusively both.”